4 February 2022
The ESMO Congress 2021 saw results of a Phase 3 trial of ribociclib, a CDK4/6 inhibitor, that showed a median overall survival of 63.9 months for metastatic breast cancer with a good safety profile, besides maintaining quality of life with a 12-month delay for chemotherapy.